# China NMPA Drug Inspection - Fujian Mengshi Pharmaceutical Co., Ltd. - Atractylodes lancea

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/fujian-mengshi-pharmaceutical-co-ltd/99914a17-85b6-4947-ba5b-a20b0bf744a1/
Source feed: China

> China NMPA drug inspection for Fujian Mengshi Pharmaceutical Co., Ltd. published May 18, 2018. Drug: Atractylodes lancea. The Heilongjiang Provincial Food and Drug Administration announced on May 18, 2018, the discovery of ten batches of subs

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Heilongjiang Provincial Food and Drug Administration regarding 10 batches of substandard traditional Chinese medicine decoction pieces (Issue No. 5, 2018)
- Company Name: Fujian Mengshi Pharmaceutical Co., Ltd.
- Publication Date: 2018-05-18
- Drug Name: Atractylodes lancea
- Inspection Finding: The non-compliant items were content determination, inspection, and identification.
- Action Taken: The relevant food and drug administration departments have taken control measures such as sealing and seizing, and have required the sampled units to stop selling and using the batch of products; they have also initiated investigations into illegal acts of selling and using substandard Chinese herbal medicine pieces, and transferred cases suspected of constituting crimes to the public security departments in accordance with the law.
- Summary: The Heilongjiang Provincial Food and Drug Administration announced on May 18, 2018, the discovery of ten batches of substandard Traditional Chinese Medicine (TCM) pieces following tests by various inspection institutes. The announcement pertains to products from multiple companies, including Hebei Jixintang Pharmaceutical Co., Ltd., Fujian Hengxin Pharmaceutical Co., Ltd., and several others from Hebei, Heilongjiang, Anhui, and Jilin provinces.

Key violations identified across the products included issues with content determination, visual appearance, product identification, and general inspection standards. Notably, some cases involved products with labeled manufacturers that either denied production, had ceased operations, or had their production licenses revoked, indicating significant challenges in product traceability and potential instances of fraudulent labeling. For example, a product labeled from Heilongjiang Hexiangchun Traditional Chinese Medicine Pieces Co., Ltd. was confirmed not to have been produced by that company.

Under the framework of the *Drug Administration Law of the People's Republic of China*, specific actions have been mandated. Food and drug administration departments where the samples originated have initiated control measures, including sealing and seizing the substandard batches, and requiring units to cease their sale and use. Furthermore, these departments are required to investigate and prosecute the illegal sale and use of these products, referring any suspected criminal cases to public security departments. The results of these enforcement actions must be publicly disclosed within three months, with reports submitted to the Provincial Bureau.

Company: https://www.globalkeysolutions.net/companies/fujian-mengshi-pharmaceutical-co-ltd/545ead2b-7c00-4d94-b54f-e266d3618d89/